Journal of Pharmacology, Genetics and Molecular Biology (JPGMB)
ISSN: 3049-3757 | Vol. 01, Issue-05, Sep-Oct, 2025

New Horizons in The Treatment of Ovarian Cancer

Phanse Milind Dilip[1*], Sujit Vitthal Abhang[1], Kirti C. Godse[1], Dipali S. Salunkhe2, Pawar Shravani Prakash[1]

[1]Arvind Gavli College of Pharmacy, Jaitapur, Satara, 415004

[2]Krishna Institute of Pharmacy, Karad, Pin-415539

***Corresponding Author E-mail: phansemilind4@gmail.com**

ABSTRACT

Ovarian cancer is one of the most fatal gynecological cancers because of its asymptomatic development, delayed detection, elevated recurrence rates, and resistance to chemotherapy, highlighting the critical need for novel treatment approaches. Pre-clinical research using various animal models—such as syngeneic, xenograft, and genetically altered mice—have been crucial in clarifying tumor biology, immunological interactions, metastatic behavior, and treatment responses. These models enable systematic assessment of traditional chemotherapies, targeted treatments, immunotherapies, and nanotechnology-based drug delivery systems, offering insights into effectiveness, pharmacokinetics, toxicity, and resistance mechanisms in an in vivo setting. Syngeneic models facilitate the exploration of immune-mediated therapy, xenografts provide the evaluation of human tumor-targeted interventions, and genetically altered mice mimic critical genetic alterations and tumorigenic pathways, hence augmenting translational value. Pre-clinical data indicate that novel therapies—such as PARP inhibitors, VEGF antagonists, immune checkpoint inhibitors, and nanoparticle-based therapeutic formulations—can enhance tumor shrinkage, extend life, and diminish systemic toxicity. Notwithstanding their limitations, such as the poor reproduction of human tumor heterogeneity and disparities in immune systems, animal models are essential for connecting laboratory research with therapeutic application. This review consolidates advancements in animal-based ovarian cancer research, assesses model-specific advantages and disadvantages, and underscores the incorporation of traditional and novel medicines to formulate safer, more effective, and individualized treatment approaches.

Key Words:

Keywords: Ovarian Cancer, Animal Models, Syngeneic Mice, Xenograft, Genetically Engineered Mice, Pre-Clinical Studies

Article History:

Received on July 26, 2025

Revised on Aug 29, 2025

Accepted on Sep 28, 2025

Published on Oct 14, 2025

DOI: https://doi.org/10.64062/JPGMB.Vol1.Issue5.9

1. INTRODUCTION

Due mainly to its silent development in the early stages and the fact that most patients get a late diagnosis, ovarian cancer continues to rank among the most deadly gynecological cancers in the world[1]. Although survival results have been somewhat improved by traditional treatment techniques such surgery, platinum-based chemotherapy, and radiation, recurrence rates are still high, and drug resistance is still a major problem. Over the last several decades, the general prognosis for advanced ovarian cancer has not much improved, despite improvements in surgical procedures and diagnostic imaging. Because of this unmet clinical need, scientists and

medical professionals are investigating new therapeutic approaches that have the potential to increase patient survival, lessen side effects, and get around the drawbacks of traditional therapies[2].



Figure 1: Ovarian Cancer

Through the combination of immunotherapy, targeted drug delivery, and molecular biology, major advancements in the treatment of ovarian cancer have been accomplished in recent years[3]. Novel approaches to personalized medicine have been made possible by technologies including immunotherapeutic agents, monoclonal antibodies, angiogenesis inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, and nanocarrier-based drug delivery systems. The molecular heterogeneity of ovarian cancer has also been better understood because to developments in proteomics and genomics, opening the door for precision-targeted treatments that may increase treatment effectiveness. These novel therapeutic approaches not only raise the prospect of improved clinical results but also emphasize the value of translational research in closing the knowledge gap between lab results and practical clinical applications.

1.1.Background Information and Context

Animal models of ovarian cancer have long been used to study the disease's etiology, development, and treatment outcomes[4]. Due to the rarity of spontaneous ovarian cancer in most animals, scientists have created a number of experimental models, including chemically produced ovarian tumors in rodents, xenograft models employing human ovarian cancer cell lines, genetically modified mice, and patient-derived xenografts (PDXs). These animal models provide a controlled setting for examining the biology of diseases and testing new treatment modalities prior to moving on to clinical research. The ability to replicate the tumor microenvironment, angiogenesis, immune response, and metastatic behavior of ovarian cancer in particular has been crucial in enabling researchers to test drug efficacy, pharmacokinetics, and toxicity in a manner that closely resembles human disease conditions[5].

Findings from these animal-based research have greatly influenced the search for novel treatment options for ovarian cancer. According to preclinical studies, targeted treatments such

immune checkpoint inhibitors, VEGF (vascular endothelial growth factor) blockers, and PARP inhibitors may dramatically reduce tumor development and increase survival in rodent models[6]. In a similar vein, animals with generated or transplanted ovarian tumors have shown enhanced bioavailability, selective tumor targeting, and decreased systemic toxicity when using drug delivery methods based on nanotechnology, such as liposomes, polymeric nanoparticles, and dendrimers. Additional potential approaches have been identified via animal immunotherapy research, including as monoclonal antibody treatment, adoptive T-cell transfer, and cancer vaccines, all of which improve the host immune system's capacity to identify and eliminate tumor cells[7]. By bridging the gap between laboratory innovation and clinical translation, these animal-based research together provide the scientific groundwork for improving the treatment of ovarian cancer and emphasize the critical role that pre-clinical models play in guiding future therapeutic approaches[8].

1.2.Objective of the review

1. To provide a comprehensive overview of animal models used in ovarian cancer research, highlighting their role in replicating tumor biology, microenvironment, and metastatic pathways.
2. To critically examine pre-clinical studies exploring conventional and emerging therapeutic approaches such as chemotherapy, targeted therapy, immunotherapy, and nanotechnology-based drug delivery in animal models of ovarian cancer.
3. To analyze the pharmacological advantages and limitations of novel treatments demonstrated in animal-based studies, including their effects on tumor regression, survival outcomes, and systemic toxicity.
4. To identify translational gaps between animal research and clinical application, with a focus on the strengths and weaknesses of current pre-clinical models in predicting therapeutic success.
5. To suggest future directions for ovarian cancer treatment research, emphasizing the refinement of animal models, integration of multidisciplinary therapeutic strategies, and development of safer, more effective treatment modalities.

1.3.Importance of the Topic

As ovarian cancer continues to be one of the most deadly gynecological cancers with poor survival rates, it is crucial to investigate novel therapeutic options using animal models[9]. Given that they closely resemble the tumor biology, metastasis, and response to treatment seen in human ovarian cancer, animal models are essential for bridging the gap between fundamental research and clinical translation[10]. By concentrating on pre-clinical research, this review highlights the need of looking into cutting-edge treatment approaches that are often proven in animals before moving on to human trials, such as targeted therapy, immunotherapy, and drug delivery systems based on nanotechnology[11]. Understanding these developments not only clarifies the safety, effectiveness, and mechanisms of action of new medicines, but it also draws attention to the obstacles and constraints that prevent successful translation[12]. This subject is thus very relevant as it incorporates existing information, assesses advancements in pre-clinical

techniques, and highlights the possibility of creating safer, more efficient, and patient-specific treatments in the future to fight ovarian cancer.

2. PRE-CLINICAL STUDIES IN OVARIAN CANCER

Research on ovarian cancer is based on pre-clinical investigations, which provide vital information about tumor biology, disease processes, and treatment outcomes prior to being translated into clinical applications[13]. The intricate tumor microenvironment, growth patterns, and metastatic behavior seen in ovarian cancer are crucially replicated by animal models, in particular[14]. The biology of the illness and the pharmacological effects of new treatments may be examined using these models, which allow researchers to assess how tumors interact with surrounding tissues, vasculature, and immune cells[15]. To simulate the formation and spread of ovarian tumors, animal models—such as syngeneic, xenograft, and genetically modified mice—have been used extensively throughout the years. Under carefully monitored experimental settings, these models provide the chance to test new targeted drugs, immunotherapies, traditional chemotherapies, and formulations based on nanotechnology.

Pre-clinical studies are crucial because they may help close the gap between research in the lab and clinical use[16]. They make it possible to systematically evaluate aspects of treatment effectiveness, drug distribution, toxicity, and resistance mechanisms that are difficult to measure in vitro alone[17]. Moreover, researchers may examine tumor regression, survival advantages, and systemic adverse effects in a whole-organism setting by using animal-based models, which offers useful predictive information for possible human use. Pre-clinical research continue to be essential in forming the therapeutic pipeline for ovarian cancer, despite several drawbacks, such as the unpredictability in reproducing real tumor heterogeneity. They show the difficulties that need to be overcome in order to guarantee safety, effectiveness, and translational relevance in clinical practice going forward, in addition to highlighting the potential of novel treatments.

2.1.Summary of Key Research Studies

Numerous animal models have been used extensively in pre-clinical research on ovarian cancer, each of which has provided unique insights into tumor biology and treatment assessment[18]. The effectiveness of checkpoint inhibitors, cytokine treatments, and other immune-modulating techniques in improving survival and inhibiting tumor development has been shown via the use of syngeneic animals to study immune–tumor interactions[19]. The evaluation of chemotherapeutics, targeted agents, and sophisticated nanocarrier-based drug delivery systems has been made possible by xenograft models, which involve transplanting human ovarian cancer cells into immunocompromised mice. These models have demonstrated notable enhancements in tumor regression, drug bioavailability, and decreased systemic toxicity[20]. A more therapeutically relevant platform for evaluating targeted and combinatorial therapy is provided by genetically engineered mice models (GEMMs), which have recreated the genetic abnormalities and tumorigenic pathways underpinning the development, resistance, and metastasis of ovarian cancer. When taken as a whole, these studies demonstrate the many ways in which animal models have advanced our knowledge of ovarian cancer and helped to develop new therapeutic strategies that might close the gap between research results in the lab and clinical settings.

1. To investigate immune–tumor interactions and treatment responses within an intact immune system, syngeneic mice models have been widely used in ovarian cancer research. By implanting ovarian cancer cells into immunocompetent mice, these models enable the assessment of immunotherapies such cytokine-based therapies and checkpoint inhibitors. Research has shown that immune-modulating substances may increase anti-tumor action, inhibit tumor growth, and enhance mouse survival. These results show immune evasion pathways that may be targeted for therapeutic benefit and provide important insights into the possible role of immunological-based treatments in managing ovarian cancer[21].
2. Chemotherapies, targeted medicines, and drug delivery systems based on nanocarriers have all been evaluated using xenograft models, which involve transplanting human ovarian cancer cells into immunocompromised mice. Compared to free medicines, studies have shown that chemotherapeutics loaded into nanoparticles exhibit better drug accumulation in tumor tissues, extended drug circulation, and less systemic toxicity. For instance, paclitaxel or cisplatin-delivering liposome-encapsulated and polymeric nanoparticles have shown significant tumor regression and improved tolerability in animal systems. These results demonstrate how xenograft models allow for the controlled testing of novel drug formulations that might get beyond the drawbacks of traditional chemotherapeutics[22].
3. By simulating the genetic abnormalities and progressive carcinogenesis linked to ovarian cancer, genetically modified mouse models (GEMMs) provide a more physiologically appropriate method[23]. Changes in tumor suppressor genes and oncogenes are what propel cancer growth, chemoresistance, and metastatic dissemination, according to studies using GEMMs. These models have also been crucial for pre-clinical testing of combination regimens and targeted medicines, providing important information on the processes behind treatment resistance. Studies on the use of nanotechnology-based drug delivery in GEMMs have also shown that by focusing medication activity inside the tumor microenvironment, nanoparticle formulations not only increase therapeutic index but also extend life. These animal-based research together highlight the potential of new treatment avenues for ovarian cancer while also highlighting the obstacles that need to be overcome prior to clinical translation.

2.2.Methodologies and Findings

Numerous animal-based techniques have been used in pre-clinical research on ovarian cancer in order to mimic the genesis, development, and response to treatment of tumors. Syngeneic mouse models are often used to investigate immune–tumor interactions and assess immunotherapies[24]. They are produced by injecting immunocompetent animals with murine ovarian cancer cells. Important discoveries from these models include the capacity of cytokine-based treatments and checkpoint inhibitors to improve anticancer immune responses, increase survival, and lessen the spread of metastases[25]. Chemotherapy regimens, targeted inhibitors, and sophisticated drug delivery systems have all been tested using xenograft models, which are created by implanting human ovarian cancer cells or patient-derived tumor tissues into immunodeficient mice. Results from these animals demonstrate that liposomal formulations and medicines encapsulated in nanoparticles greatly enhance drug stability, tumor-specific accumulation, and therapeutic effectiveness while reducing systemic toxicity. The most

accurate representation of the pathophysiology of human ovarian cancer is provided by genetically modified mice models (GEMMs), which include mutations in genes including TP53, BRCA1/2, and KRAS. In addition to providing reliable platforms for evaluating combinatorial treatment approaches, methodological developments in GEMMs have provided important new insights into the processes behind tumor heterogeneity, resistance to platinum-based chemotherapy, and metastatic behavior. When taken as a whole, these animal-based techniques provide thorough and applicable results that guide the development of safer and more efficient therapies for ovarian cancer.

2.3.Strengths and Weaknesses

In the study of ovarian cancer, pre-clinical animal models have significant benefits as well as intrinsic drawbacks that influence their use in treatment investigation. Their ability to mimic tumor biology, including interactions with the immune system, vascular, and milieu, provides a dynamic platform that is essential for comprehending the course of the illness and assessing the effectiveness of therapy[26]. Because in vitro tests are unable to fully capture medication distribution, toxicity, survival outcomes, and resistance mechanisms, these models facilitate whole-organism research. They also enable the controlled testing of a variety of treatment approaches, including immunotherapy, targeted therapy, chemotherapy, and delivery systems based on nanocarriers[27]. However, flaws still exist in spite of these advantages. The genetic and metabolic heterogeneity of human ovarian cancer cannot be accurately modeled by animal models, which often reduces the predictive usefulness of findings. Accurate assessment of immunotherapies is limited by immunodeficient animals in particular, and widespread usage is made more difficult by ethical, economical, and logistical issues. Translational gaps between pre-clinical success and clinical application may also arise from the diversity of various animal models, which can provide conflicting results.

- **Strengths:** In pre-clinical ovarian cancer research, animal models have many advantages that make them essential for developing treatment approaches. Their capacity to imitate the tumor microenvironment, especially in syngeneic and genetically modified mice models, which closely resemble tumor–stroma and tumor–immune interactions, is one of their main advantages. This offers a dynamic and realistic platform for assessing possible therapies' effectiveness in a physiologically relevant setting. By allowing the evaluation of drug metabolism, biodistribution, systemic toxicity, and survival outcomes, animal research, in contrast to in vitro techniques, also provide whole-organism insights and provide discoveries with more translational value. Furthermore, under regulated and repeatable experimental circumstances, these models allow the testing of a broad variety of novel medicines, from traditional chemotherapy to more sophisticated modalities including targeted therapy, immunotherapy, and drug delivery systems based on nanotechnology. The creation of more effective and long-lasting treatment plans is made possible by the use of animal models, which are crucial for investigating drug resistance and metastasis routes, two important facets of ovarian cancer progression and recurrence.

3. **Weaknesses:** Animal models have a number of intrinsic flaws that restrict their translational accuracy, despite the fact that they are essential to the advancement of ovarian cancer research. Even the most sophisticated models are unable to accurately recreate the genetic complexity, tumor heterogeneity, and disease development patterns

seen in actual ovarian cancer, which is a major disadvantage. This limits the data' predictive power as they go from pre-clinical to clinical phases. Furthermore, immune system differences provide a major obstacle, especially in immunodeficient xenograft models, which make it impossible to properly assess immune-based treatments and hence leave gaps in the creation of immunotherapeutic approaches. In addition to biological restrictions, animal research is often costly, time-consuming, and subject to ethical guidelines, all of which may limit the range of studies and impede the rate of advancement. Additionally, differences in animal models might provide contradictory results, making comparisons more difficult, decreasing repeatability, and postponing the clinical translation of promising treatments.

4. CONVENTIONAL AND EMERGING THERAPEUTIC APPROACHES IN PRE-CLINICAL STUDIES

A crucial platform for assessing both established and novel therapy modalities before they are taken into consideration for clinical translation is pre-clinical research in ovarian cancer[28]. Because they can replicate the tumor microenvironment, disease development, and metastatic behavior under carefully monitored experimental circumstances, animal models—especially murine systems like syngeneic, xenograft, and genetically modified mice—are essential to these studies[29]. With the use of these models, scientists may methodically evaluate the pharmacokinetics, toxicity, mechanism of action, and effectiveness of different treatments in a real organism, offering insights that are hard to get in in vitro systems.

In pre-clinical animal investigations, conventional therapy techniques mostly include chemotherapeutic drugs such combination regimens, taxanes (paclitaxel, docetaxel), and platinum-based medicines (cisplatin, carboplatin). These medications have been shown in animal-based studies to significantly decrease tumor burden, induce tumor regression, and increase survival in xenograft and syngeneic ovarian cancer models. Optimizing dosage schedules and combination methods requires the examination of drug resistance mechanisms, including the emergence of multidrug-resistant tumor morphologies, which is made easier by such research. Through the observation of systemic toxicity and off-target effects in whole organisms, pre-clinical investigations aid in the development of safe and efficient treatment plans[30].

Advanced drug delivery methods, such as formulations based on nanotechnology, immunotherapies, and targeted medicines are examples of emerging therapeutic techniques. Targeted treatments, such as receptor tyrosine kinases, poly (ADP-ribose) polymerase (PARP), and vascular endothelial growth factor (VEGF) inhibitors, have demonstrated encouraging outcomes in decreasing tumor angiogenesis, preventing tumor growth, and improving sensitivity to traditional chemotherapy when tested in animal models. Immunotherapeutic approaches, including as adoptive cell treatments and immune checkpoint inhibitors, are mostly studied in syngeneic animals that preserve healthy immune systems[31]. This allows for the investigation of immune regulation, tumor–immune interactions, and anti-tumor immune responses. Furthermore, the potential of nanocarrier-based drug delivery systems, including lipid-based carriers, liposomes, and polymeric nanoparticles, to increase targeted delivery to tumors, improve drug solubility, extend retention duration, and lessen systemic toxicity is assessed in animal models. Preclinical research using these cutting-edge delivery methods has

shown better therapeutic indices, decreased metastatic dissemination, and increased tumor regression in ovarian cancer models.

Pre-clinical animal research provides a comprehensive and controlled setting for evaluating the whole range of established and novel treatments. Mechanistic insights into drug action, tumor growth, metastasis, and resistance pathways are also revealed, in addition to crucial effectiveness and safety data. By using these animal models, scientists may find viable drug candidates, improve therapeutic approaches, and provide solid proof to back the development of novel ovarian cancer therapies for translational uses in the future[32].

5. OVERVIEW OF ANIMAL MODELS IN OVARIAN CANCER RESEARCH

In the study of ovarian cancer, animal models have become essential resources that provide a vital connection between basic laboratory research and possible therapeutic uses. The complex molecular processes of ovarian cancer, such as tumor development, progression, angiogenesis, metastasis, and response to therapeutic approaches, may be replicated in a live organism using these models[33]. Animal models capture the intricate connections between tumor cells, immunological components, stromal cells, and the vascular network, in contrast to in vitro cell culture techniques that provide little insight into systemic interactions. With a more realistic evaluation of tumor activity and treatment responses made possible by this all-encompassing methodology, prospective therapy results may be predicted.

Numerous animal models have been created to investigate various facets of the biology of ovarian cancer, each offering special benefits and research possibilities[34]. Tumor–immune system interactions, immunotherapy responses, and immune-mediated mechanisms of tumor suppression or escape may all be thoroughly examined using syngeneic models, which include transplanting tumor cells into immunocompetent animals with the same genetic background. The effectiveness, pharmacokinetics, and toxicity of chemotherapeutic drugs, targeted treatments, and innovative drug delivery methods are often assessed using xenograft models, which include implanting human ovarian cancer cells or tissues into immunocompromised mice. These models preserve features of real tumor biology while offering a platform for testing therapeutic approaches in a controlled setting. In order to examine the onset, development, and metastasis of ovarian cancer in a way that closely mimics the genetic and molecular landscape of humans, genetically modified mice models (GEMMs) are made to carry certain genetic abnormalities linked to the illness. GEMMs are very useful for assessing targeted therapeutics in a genetically relevant setting and for comprehending the function of tumor suppressor and oncogene genes.

When taken as a whole, these animal models enable thorough pre-clinical testing of traditional chemotherapy, new targeted treatments, immunotherapies, and drug delivery methods based on nanotechnology. In order to create long-lasting and successful treatment plans, they also provide vital insights into the processes behind drug resistance, tumor recurrence, and metastatic dissemination. Researchers may examine several aspects of tumor biology and treatment response by combining the use of syngeneic, xenograft, and genetically modified models, even though no one model can accurately capture the complexity and variability of actual ovarian cancers. The creation of novel therapeutic approaches, the advancement of pre-clinical ovarian cancer research, and the guidance of upcoming translational and clinical studies targeted at enhancing patient outcomes are all made possible by these models.

Table 1: Summary of Animal Models Used in Preclinical Ovarian Cancer Research

Authors & Year	Animal Model Used	Study Focus / Aim	Key Findings	Significance / Contribution
Magnotti & Marasco, 2018 [35]	Mouse models (syngeneic, xenograft, GEMMs)	Review of latest animal models for drug discovery in ovarian cancer	Highlighted advances in ovarian cancer models including genetically engineered mice and patient-derived xenografts; emphasized models for evaluating novel therapeutics	Provided a comprehensive overview of current pre-clinical models supporting drug development pipelines
Tudrej, Kujawa, Cortez & Lisowska, 2019 [36]	Murine models, xenografts	Characteristics of in vivo ovarian cancer models	Identified advantages and limitations of existing in vivo models, including immune system interactions and tumor heterogeneity	Offered guidance on selecting appropriate models for pre-clinical studies
Karakashev & Zhang, 2021 [37]	Mouse models (epithelial ovarian cancer)	Preclinical modeling of epithelial ovarian cancer	Discussed use of genetically engineered and syngeneic models for studying tumor progression, metastasis, and therapeutic response	Emphasized translational relevance of mouse models in preclinical evaluation
Tsang, Hassan, To & Wong, 2022 [38]	Rodent models	Experimental models for ovarian cancer research	Reviewed methodologies including xenograft implantation and transgenic mouse approaches; evaluated efficacy of pre-clinical interventions	Provided a framework for designing animal-based ovarian cancer experiments
Zakarya, Howell & Colvin, 2020 [39]	Mouse models (classical & emerging)	Modeling epithelial ovarian cancer in mice	Discussed classical xenograft and emerging genetically engineered approaches;	Clarified the strengths and weaknesses of various mouse models for

			highlighted tumor microenvironment modeling	therapeutic studies
Simonsen et al., 2025 [40]	Rodent models (peritoneal chemotherapy delivery)	Systematic review of peritoneal chemotherapy systems in ovarian cancer	Evaluated efficacy, distribution, and toxicity of chemotherapeutic delivery methods in animal models	Provided evidence-based insights for optimizing pre-clinical delivery systems for ovarian cancer therapy

6. DISCUSSION

An essential basis for understanding the biology of ovarian cancer and developing treatment approaches is provided by pre-clinical animal research. In a controlled, whole-organism setting, researchers may examine tumor genesis, development, metastasis, and response to traditional and novel therapies by using a variety of models, including syngeneic, xenograft, and genetically modified mice. Together, these studies show how complicated ovarian cancer is and how using animal models may help close the gap between research findings in the lab and possible therapeutic uses. The interpretation of the results, their wider implications, and potential future study avenues are covered in detail in the next subsections.

6.1.Interpretation and Analysis of Findings

Every animal model offers distinct insights into the pathogenesis of ovarian cancer and the effectiveness of treatment, according to a study of pre-clinical research. In order to assess immunotherapies such checkpoint inhibitors and cytokine-based treatments, syngeneic mice models are very useful for researching immune–tumor interactions. In syngeneic models, these research show that healthy immune systems are essential for comprehending immune evasion pathways and refining immune-modulating tactics. Xenograft models, which are created by transplanting human ovarian cancer cells into immunocompromised mice, are highly useful for evaluating targeted medicines, chemotherapeutic drugs, and drug delivery systems based on nanotechnology. The results consistently demonstrate that improved delivery technologies, such as polymeric nanoparticles and liposomes, improve therapeutic effectiveness, tumor targeting, and drug bioavailability while lowering systemic toxicity. By simulating particular genetic alterations, tumor heterogeneity, and metastatic activity, genetically modified mouse models (GEMMs) provide extra translational significance. Understanding the processes behind chemoresistance, tumor recurrence, and combinatorial therapy strategy evaluation have all benefited greatly from these models. The pre-clinical results taken together highlight the fact that no single model is adequate by itself; rather, the most thorough knowledge of ovarian cancer biology and treatment response may be obtained by combining many models.

6.2.Implications and Significance

The results of research conducted on animals have significant ramifications for the study and development of treatments for ovarian cancer. First, they draw attention to how important the

tumor microenvironment, immune responses, and genetics are in influencing the course of therapy. Pre-clinical studies are crucial for refining treatment regimens before clinical trials because they properly simulate these traits and provide predictive insights for medication effectiveness, toxicity, and resistance. Targeted inhibitors, immunotherapies, and nanocarrier-based drug delivery are examples of developing techniques that have shown promise in improving tumor control while reducing systemic side effects. The significance of precision medicine approaches—where treatments are customized to particular tumor features and genetic profiles—is further highlighted by the translational insights gleaned from these investigations. Pre-clinical research essentially ensures a greater chance of therapeutic success in human patients by validating possible treatment approaches and guiding the design of subsequent clinical trials.

6.3.Gaps and Future Research Directions

Current animal models have several shortcomings that need to be fixed in order to increase translational relevance, notwithstanding their advantages. Human tumor heterogeneity, which includes differences in genetic alterations, stromal interactions, and metastatic activity, is one of the main limitations. The assessment of immunotherapies is limited by immunodeficient xenograft models, which are helpful for drug testing but fall short in capturing the intricacy of immune-mediated responses. Furthermore, logistical, budgetary, and ethical limitations provide difficulties for lengthy or extensive research. Variability across models makes it much more difficult to assess and extrapolate results.

Subsequent investigations have to concentrate on improving animal models to more closely resemble human ovarian cancer, either by using humanized mouse models or sophisticated GEMMs that integrate several genetic and microenvironmental characteristics. In order to improve therapeutic effectiveness and safety, it should be a priority to integrate interdisciplinary techniques, such as integrating nanotechnology with immunotherapy or targeted therapy. Additionally, pre-clinical study techniques that are standardized might enhance laboratory comparability and reproducibility. Ultimately, the development of novel, patient-specific ovarian cancer treatments will depend on translational research projects that connect pre-clinical discoveries with clinical trials.

7. CONCLUSION

In conclusion, the use of animal-based pre-clinical research to explore novel avenues for the treatment of ovarian cancer highlights the critical role that these models play in promoting therapeutic innovation and bridging the translational gap to clinical application. Understanding the intricate biology of ovarian cancer, including tumor origin, development, metastasis, immunological interactions, and response to treatment, has been made possible by the use of animal models, such as syngeneic, xenograft, and genetically modified mice. While newer approaches like targeted therapies, immunotherapies, and nanocarrier-based drug delivery systems have shown improved efficacy, specificity, and safety in vivo, traditional chemotherapeutics like platinum-based agents and taxanes have been successfully assessed for tumor regression, drug resistance mechanisms, and systemic toxicity. While xenograft models enable accurate assessment of human tumor cell responses and sophisticated drug formulations, syngeneic models have uncovered crucial immune–tumor interactions that guide the development of checkpoint inhibitors and cytokine treatments. The genetic and molecular

makeup of human ovarian cancer is replicated in genetically modified mice models, providing a platform for evaluating combination treatments and clarifying chemoresistance pathways. These models continue to be essential in pre-clinical research, offering predictive data that directs clinical trial design and therapeutic optimization, despite their inherent limitations, which include incomplete recapitulation of tumor heterogeneity, immune discrepancies, ethical constraints, and translational variability. Together, the results show that using an integrative and multidisciplinary approach in animal research not only advances our knowledge of the pathophysiology of ovarian cancer but also speeds up the creation of safer, more individualized, and more successful treatment plans. This approach may eventually help improve patient outcomes and meet the unmet clinical needs in this deadly cancer.

REFERENCES

1. Lee, J. M., Minasian, L., & Kohn, E. C. (2019). New strategies in ovarian cancer treatment. *Cancer*, *125*, 4623-4629.
2. Srirangaramasamy, J. (2024, April). BREAKING GROUND: LATEST INNOVATIONS AND THERAPIES IN OVARIAN CANCER TREATMENT. In *Obstetrics & Gynaecology Forum* (Vol. 34, No. 2).
3. Abolhasani Zadeh, F., Shahhosseini, E., Rasoolzadegan, S., Özbolat, G., & Farahbod, F. (2022). Au nanoparticles in the diagnosis and treatment of ovarian cancer: A new horizon in the personalized medicine. *Nanomedicine Research Journal*, *7*(1), 1-18.
4. Khatoon, E., Parama, D., Kumar, A., Alqahtani, M. S., Abbas, M., Girisa, S., ... & Kunnumakkara, A. B. (2022). Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy. *Life Sciences*, *306*, 120827.
5. Ding, H., Zhang, J., Zhang, F., Xu, Y., Liang, W., & Yu, Y. (2022). Nanotechnological approaches for diagnosis and treatment of ovarian cancer: a review of recent trends. *Drug Delivery*, *29*(1), 3218-3232.
6. Zoń, A., & Bednarek, I. (2023). Cisplatin in ovarian cancer treatment—known limitations in therapy force new solutions. *International journal of molecular sciences*, *24*(8), 7585.
7. Srivastava, M., Ahlawat, N., & Srivastava, A. (2021). Ovarian cancer stem cells: newer horizons. *The Journal of Obstetrics and Gynecology of India*, *71*(2), 115-117.
8. O'Malley, D. M. (2019). New therapies for ovarian cancer. *Journal of the National Comprehensive Cancer Network*, *17*(5.5), 619-621.
9. Zhang, J., Ding, H., Zhang, F., Xu, Y., Liang, W., & Huang, L. (2023). New trends in diagnosing and treating ovarian cancer using nanotechnology. *Frontiers in Bioengineering and Biotechnology*, *11*, 1160985.
10. Caruso, G., Coleman, R. L., Aletti, G., Multinu, F., Botticelli, A., Palaia, I., ... & Colombo, N. (2023). Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon?. *International Journal of Gynecological Cancer*, *33*(9), 1448-1457.
11. Bachmann, C. (2023). New achievements from molecular biology and treatment options for refractory/relapsed ovarian cancer—a systematic review. *Cancers*, *15*(22), 5356.

12. Tundo, G. R., Sbardella, D., Lacal, P. M., Graziani, G., & Marini, S. (2019). On the horizon: targeting next-generation immune checkpoints for cancer treatment. *Chemotherapy*, *64*(2), 62-80.
13. Lago, V., & Domingo, S. (2020). New horizons of sentinel lymph node technique in early ovarian cancer. *American Journal of Obstetrics & Gynecology*, *222*(1), 94.
14. Stewart, C., Ralyea, C., & Lockwood, S. (2019, April). Ovarian cancer: an integrated review. In *Seminars in oncology nursing* (Vol. 35, No. 2, pp. 151-156). WB Saunders.
15. Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019). Epithelial ovarian cancer. *The Lancet*, *393*(10177), 1240-1253.
16. Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019). Ovarian cancer in the world: epidemiology and risk factors. *International journal of women's health*, 287-299.
17. Arora, T., Mullangi, S., & Lekkala, M. R. (2021). Ovarian cancer.
18. Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., ... & Siegel, R. L. (2018). Ovarian cancer statistics, 2018. *CA: a cancer journal for clinicians*, *68*(4), 284-296.
19. Cortez, A. J., Tudrej, P., Kujawa, K. A., & Lisowska, K. M. (2018). Advances in ovarian cancer therapy. *Cancer chemotherapy and pharmacology*, *81*(1), 17-38.
20. Deb, B., Uddin, A., & Chakraborty, S. (2018). miRNAs and ovarian cancer: An overview. *Journal of cellular physiology*, *233*(5), 3846-3854.
21. Gaona-Luviano, P., Medina-Gaona, L. A., & Magaña-Pérez, K. (2020). Epidemiology of ovarian cancer. *Chinese clinical oncology*, *9*(4), 47-47.
22. Penny, S. M. (2020). Ovarian cancer: an overview. *Radiologic technology*, *91*(6).
23. Orr, B., & Edwards, R. P. (2018). Diagnosis and treatment of ovarian cancer. *Hematology/Oncology Clinics*, *32*(6), 943-964.
24. Elias, K. M., Guo, J., & Bast, R. C. (2018). Early detection of ovarian cancer. *Hematology/Oncology Clinics*, *32*(6), 903-914.
25. Qin, T., Fan, J., Lu, F., Zhang, L., Liu, C., Xiong, Q., ... & Sun, C. (2022). Harnessing preclinical models for the interrogation of ovarian cancer. *Journal of Experimental & Clinical Cancer Research*, *41*(1), 277.
26. Lu, H., Ma, L., Zhang, Y., Feng, Y., Zhang, J., & Wang, S. (2022). Current animal model systems for ovarian aging research. *Aging and Disease*, *13*(4), 1183.
27. Cybula, M., & Bieniasz, M. (2022). Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: Pre-clinical updates. *Oncotarget*, *13*, 553.
28. Stuckelberger, S., & Drapkin, R. (2018). Precious GEMMs: emergence of faithful models for ovarian cancer research. *The Journal of pathology*, *245*(2), 129-131.
29. Chang, Y. H., Wu, K. C., Harnod, T., & Ding, D. C. (2022). The organoid: A research model for ovarian cancer. *Tzu Chi Medical Journal*, *34*(3), 255-260.
30. Bolland, D. E., & McLean, K. (2019). Preclinical models in ovarian cancer. In *Animal Models in Cancer Drug Discovery* (pp. 31-57). Academic Press.
31. Kressin, M., Fietz, D., Becker, S., & Strebhardt, K. (2021). Modelling the functions of Polo-like kinases in mice and their applications as cancer targets with a special focus on ovarian cancer. *Cells*, *10*(5), 1176.

32. Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., ... & Weinberg, R. A. (2021). Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy. *Cancer Discovery*, *11*(2), 384-407.
33. Watters, K. M., Bajwa, P., & Kenny, H. A. (2018). Organotypic 3D models of the ovarian cancer tumor microenvironment. *Cancers*, *10*(8), 265.
34. Grabosch, S., Bulatovic, M., Zeng, F., Ma, T., Zhang, L., Ross, M., ... & Vlad, A. M. (2019). Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles. *Oncogene*, *38*(13), 2380-2393.
35. Magnotti, E., & Marasco, W. A. (2018). The latest animal models of ovarian cancer for novel drug discovery. Expert opinion on drug discovery, 13(3), 249-257.
36. Tudrej, P., Kujawa, K. A., Cortez, A. J., & Lisowska, K. M. (2019). Characteristics of in vivo model systems for ovarian cancer studies. Diagnostics, 9(3), 120.
37. Karakashev, S., & Zhang, R. G. (2021). Mouse models of epithelial ovarian cancer for preclinical studies. Zoological Research, 42(2), 153.
38. Tsang, S. I., Hassan, A. A., To, S. K., & Wong, A. S. (2022). Experimental models for ovarian cancer research. Experimental Cell Research, 416(1), 113150.
39. Zakarya, R., Howell, V. M., & Colvin, E. K. (2020). Modelling epithelial ovarian cancer in mice: classical and emerging approaches. International journal of molecular sciences, 21(13), 4806.
40. Simonsen, M., Lopez, R. V. M., Maistro, S., Ikeoka, L. T., de Lima Pereira, G. F., Lugão, A. B., ... & Folgueira, M. A. A. K. (2025). Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models. Frontiers in Oncology, 14, 1487376.